Hypera SA is a pharmaceutical company, which engages in the manufacture and distribution of medical and cosmetics products. The company is headquartered in Sao Paulo, Sao Paulo. The company went IPO on 2008-04-16. The firm operates in several markets with a variety of pharmaceutical products. The firm's products include: Mantecorp Farmasa, which is an under the umbrella brand; Addera D3, Nesina, Dramin, Alivium, Predsim, Lisador, and Rinosoro, which focus on several medical specialties involving primary care which are present in main therapeutic classes; Mantecorp Skincare, which offer dermo cosmetics recommended by dermatologists and also operates in this segment with the brands Simple Organic, which offers organic, vegan, and cruelty-free products, and Bioage, which focuses on the professional aesthetic treatment market; and Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina, which are over-the-counter medications provided throughout Brazil.
How did HYPMY's recent EPS compare to expectations?
The most recent EPS for Hypera S.A. is $0.55, beating expectations of $0.46.
How did Hypera S.A. HYPMY's revenue perform in the last quarter?
Hypera S.A. revenue for the last quarter is $0.55
What is the revenue estimate for Hypera S.A.?
According to 6 of Wall street analyst, the revenue estimate of Hypera S.A. range from $2.55B to $2.28B
What's the earning quality score for Hypera S.A.?
Hypera S.A. has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Hypera S.A. report earnings?
Hypera S.A. next earnings report is expected in 2026-07-27
What are Hypera S.A.'s expected earnings?
Hypera S.A. expected earnings is $2.06B, according to wall-street analysts.
Did Hypera S.A. beat earnings expectations?
Hypera S.A. recent earnings of $2.01B does not beat expectations.